Eric D.
- Country
- France
- Department
- oncology
Research Overview
- Phase II Evaluation of Atezolizumab Combined with Stereotactic Ablative Radiotherapy in Metastatic Colorectal, Non-Small Cell Lung, Renal Cell Carcinoma, and Sarcoma
- Phase II Study of Intratumoral KRC-01 (hydrogen peroxide) plus Radiotherapy for Clinical Complete Response in Locally Advanced Stage III Rectal Adenocarcinoma (K-BOOST)
- Evaluation of Durvalumab and Tremelimumab Combined with Stereotactic Body Radiotherapy in Metastatic Squamous Cell Carcinoma of Various Sites
Data & Insights
Has run more than one trial at 6 of 29 partner sites.
Specializations
Advanced Oncology
The investigator specializes in treating metastatic solid tumors and locally advanced cancers, with particular emphasis on innovative therapeutic approaches.
- Colorectal Cancer
- Non-small Cell Lung Cancer
- Renal Cell Carcinoma
- Cervical Cancer
Focuses on developing treatment strategies for patients with oligometastatic disease and locally advanced malignancies.
Immunotherapy Integration
Expertise in implementing immune checkpoint inhibitor therapies including the application of PD-L1 and CTLA-4 targeted treatments.
- Atezolizumab Applications
- Durvalumab Combinations
- Tremelimumab Protocols
Specializes in combining immunotherapy with other treatment modalities for enhanced therapeutic outcomes.
Radiation Oncology
Focuses on advanced radiation treatment approaches including stereotactic body radiotherapy (SBRT) and stereotactic ablative radiotherapy (SABR).
- Chemoradiotherapy Integration
- Pan-lesion SBRT Applications
- Immunoradiotherapy Combinations
Specializes in precision radiation delivery methods combined with systemic treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.